載入...
Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies
For almost a decade, systemic therapy of advanced hepatocellular carcinoma (HCC) was limited to the tyrosine kinase inhibitor (TKI) sorafenib. Different agents including checkpoint inhibitors, TKIs and anti-VEGFR antibodies demonstrated efficacy in treatment. For the first time, the combination of a...
Na minha lista:
| 發表在: | Hepat Oncol |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Future Medicine Ltd
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7338920/ https://ncbi.nlm.nih.gov/pubmed/32647565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep-2020-0004 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|